Dehydroepiandrosterone and metformin modulate progesterone-induced blocking factor (PIBF), cyclooxygenase 2 (COX2) and cytokines in early pregnant mice

Dehydroepiandrosterone to induce murine models for the study of polycystic ovary syndrome

“…In the study of metformin's intracellular mechanisms in preventing embryo resorption, we demonstrated for the first time that hyperandrogenism during early pregnancy prevents the expression of progesterone-induced blocking factor (PIBF) in the implantation sites [108]. We also demonstrated the immunolocalization of PIBF in decidua and trophoblast cells, thus, providing the first evidence that other cell types different from lymphocytes produce PIBF [108].…”

Effect of DHEA and metformin on corpus luteum in mice

“…The treatment with metformin is also able to improve uterine vascularization in PCOS patients (Palomba et al 2006). In addition, metformin prevents early embryo resorption in women with PCOS (Jakubowicz et al 2004) by regulating both the PG and NO systems (inducible and constitutive nitric oxide synthase activity), the expression of progesterone-induced blocking factor, and the production of cytokines (Luchetti et al 2008). Thus, our second objective was to investigate the action of metformin in preventing the ovarian dysfunctions produced by hyperandrogenism.…”

Link between metformin and the peroxisome proliferator-activated receptor γ pathway in the uterine tissue of hyperandrogenized prepubertal mice

“…The animal model (7)(8)(9)(10)(11) consisted of female prepubertal (25-dayold) mice of the BALB/c strain. The dehydroepiandrosterone (DHEA) group consisted of animals injected daily with DHEA (6 mg/100 g body weight, dissolved in 0.10 mL sesame oil) for 20 consecutive days, and the DHEA þ M group consisted of animals injected with DHEA and given metformin orally (50 mg/100 g body weight in 0.05 mL of water, given orally with a cannula) for 20 days.…”